ストックスクリーナーアプリを入手
5.15
4.28%
-0.23
アフターアワーズ：
5.25
0.10
+1.94%
前日終値:
$5.38
開ける：
$5.39
24時間の取引高:
1.47M
Relative Volume:
0.67
時価総額：
$758.07M
収益：
$8.37M
当期純損益:
$-69.66M
株価収益率:
-9.1899
EPS:
-0.5604
ネットキャッシュフロー:
$-51.45M
1週間 パフォーマンス:
-6.36%
1か月 パフォーマンス:
-21.19%
6か月 パフォーマンス:
+43.45%
1年 パフォーマンス:
+175.40%
1日の値動き範囲:
$5.095
$5.538
1週間の範囲:
$5.035
$5.765
52週間の値動き範囲:
$1.74
$6.5999
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Compare ACRS vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
5.15 | 758.07M | 8.37M | -69.66M | -51.45M | -0.5604 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-16 | 開始されました | Oppenheimer | Outperform |
| 2025-07-10 | 再開されました | Piper Sandler | Overweight |
| 2025-05-28 | 開始されました | Wedbush | Outperform |
| 2025-03-18 | 再開されました | Cantor Fitzgerald | Overweight |
| 2024-12-23 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | アップグレード | BTIG Research | Neutral → Buy |
| 2024-11-19 | アップグレード | Jefferies | Hold → Buy |
| 2024-11-19 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | 開始されました | Evercore ISI | Outperform |
| 2022-12-14 | 開始されました | Stifel | Buy |
| 2022-12-01 | 開始されました | Goldman | Buy |
| 2022-10-06 | 開始されました | BTIG Research | Buy |
| 2021-07-23 | 再開されました | Jefferies | Buy |
| 2021-06-15 | 開始されました | Piper Sandler | Overweight |
| 2021-04-21 | 開始されました | H.C. Wainwright | Buy |
| 2019-10-22 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | 開始されました | SVB Leerink | Outperform |
| 2018-03-28 | 再開されました | Leerink Partners | Outperform |
| 2018-02-09 | 開始されました | Guggenheim | Buy |
| 2017-06-16 | 開始されました | Cantor Fitzgerald | Overweight |
| 2016-11-29 | 開始されました | Leerink Partners | Outperform |
| 2016-09-30 | 開始されました | JMP Securities | Mkt Outperform |
| 2016-06-10 | 開始されました | Guggenheim | Buy |
| 2015-11-02 | 開始されました | Citigroup | Buy |
| 2015-11-02 | 開始されました | Jefferies | Buy |
すべてを表示
Aclaris Therapeutics Inc (ACRS) 最新ニュース
Cantor Fitzgerald reiterates Aclaris stock rating on LP opportunity - Investing.com
Cantor Fitzgerald reiterates Aclaris stock rating on LP opportunity By Investing.com - Investing.com India
Aclaris Therapeutics, Inc. (8AT.F) stock price, news, quote and history - Yahoo Finance UK
Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength? - Eastern Progress
Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade - Eastern Progress
Cantor Fitzgerald reiterates Aclaris Therapeutics stock rating By Investing.com - Investing.com Australia
Cantor Fitzgerald reiterates Aclaris Therapeutics stock rating - Investing.com
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates - Eastern Progress
Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock? - easternprogress.com
Aclaris at Cantor Fitzgerald conference: pipeline, cash, catalysts By Investing.com - Investing.com South Africa
Aclaris at Cantor Fitzgerald conference: pipeline, cash, catalysts - Investing.com
Aclaris CEO to Detail Drug Pipeline at Cantor Conference - MyChesCo
Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - Investing News Network
Canaccord initiates Aclaris stock with buy rating on pipeline potential By Investing.com - Investing.com South Africa
Canaccord initiates Aclaris stock with buy rating on pipeline potential - Investing.com India
CCORF Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating, Announces Target Price $10 - Moomoo
Canaccord Genuity Initiates Aclaris Therapeutics at Buy With $10 Price Target - Yahoo Finance
Piper Sandler reiterates Aclaris stock rating on asthma data - Investing.com India
Piper Sandler reiterates Aclaris stock rating on asthma data By Investing.com - Investing.com Canada
ETFs Investing in Aclaris Therapeutics, Inc. Stocks - TradingView
Aclaris Therapeutics (NASDAQ:ACRS) Stock: What Comes Next? - Kalkine Media
Aclaris Therapeutics (NASDAQ:ACRS) Trading 4.7% HigherWhat's Next? - MarketBeat
Aclaris Therapeutics (ACRS) Edges Lower by 1.37% as Shares Test Key Technical FloorRevenue Growth Stocks - vinanet.vn
Sei Investments Co. Makes New Investment in Aclaris Therapeutics, Inc. $ACRS - MarketBeat
Dimensional Fund Advisors LP Has $1.91 Million Stock Position in Aclaris Therapeutics, Inc. $ACRS - MarketBeat
FDA Fast Track Status Advances Aclaris Lichen Planus Drug - MyChesCo
HC Wainwright Has Pessimistic Outlook of ACRS Q3 Earnings - MarketBeat
Renaissance Technologies LLC Has $1.89 Million Stake in Aclaris Therapeutics, Inc. $ACRS - MarketBeat
Aclaris Therapeutics, Inc. (ACRS) stock price, news, quote and history - Yahoo Finance Australia
Aclaris Raises Capital as Drug Pipeline Spending Accelerates - MyChesCo
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Buy" by Brokerages - MarketBeat
Aclaris Therapeutics, Inc. (ACRS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Weekly Recap: Q2 loss, runway into 2028 and Fast Track for modzatinib - TradingView
H.C. Wainwright Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Aclaris Therapeutics (ACRS) Stock Drifts Lower As Losses Deepen On Thin Revenue - simplywall.st
Aclaris Updates At-The-Market Equity Sales Agreement - The Globe and Mail
Aclaris Therapeutics (NASDAQ:ACRS) Stock Price Down 6%Here's What Happened - MarketBeat
US FDA Fast-tracks Aclaris’ Modzatinib for Lichen Planus - The Dermatology Digest
FDA grants fast track status to Aclaris’ lichen planus drug By Investing.com - Investing.com Nigeria
Craig-Hallum Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP) - The Manila Times
Aclaris Therapeutics Inc (8AT.MU) Analyst insights, Price targets and Recommendations - Yahoo Finance Australia
Aclaris Therapeutics (NASDAQ:ACRS) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Aclaris Therapeutics (ACRS) Releases Q2 2026 Earnings: Revenue Declines, Losses Narrow - Quiver Quantitative
FDA grants fast track status to Aclaris’ lichen planus drug - Investing.com
Aclaris Therapeutics (NASDAQ: ACRS) widens loss as R&D spending accelerates - Stock Titan
Form 8K Aclaris Therapeutics Inc For: 6 August By Investing.com - Investing.com South Africa
Aclaris Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (ACRS) Aclaris Therapeutics, Inc. Reports Q2 Revenue $1.6M, vs. FactSet Est of $1.4M - marketscreener.com
Earnings Flash (ACRS) Aclaris Therapeutics Posts Q2 Net Loss $0.15 a Share, vs. FactSet Est of $0.16 Loss - marketscreener.com
Aclaris Therapeutics reports Q2 2026 net loss of $21.5M, cash runway through 2028 - TradingView
Aclaris Therapeutics Inc (ACRS) 財務データ
収益
当期純利益
現金流量
EPS
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):